Fintel reports that on April 28, 2025, HSBC downgraded their outlook for Eli Lilly and (NYSE:LLY) from Buy to Reduce. Analyst ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

The fund owned 14,848 shares of the company’s stock after selling 1,614,296 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Eli Lilly and Company were worth $ ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we ...

0.13% of the stock is currently owned by insiders. Hedge Funds Weigh In On Eli Lilly and Company Institutional investors have recently modified their holdings of the company. Breakwater Capital ...

Total shares owned by institutions increased in the last three months by 1.81% to 887,775K shares. Lilly Endowment holds 96,017K shares representing 10.69% ownership of the company. In its prior ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...

Eli Lilly is suing four telemedicine companies ... The lawsuit claims neither company is owned by a physician, and that the telehealth companies exert influence and control over their supposedly ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...